VEGFA and age-related macular degeneration: Treatment involves intravitreal administration of agents that reduce intraocular concentrations of VEGF, a proangiogenic factor that plays a key role in the formation of pathological neovascularization in the course of exudative AMD [6,7,8,9,10,11].